Salvage of refractory post-transfusion hyperhaemolysis by targeting hyperinflammation and macrophage activation with tocilizumab He was not on a regular transfusion programme and had not received further transfusion since the last operation in 2018. Treatment of post-transfusion hyperhaemolysis syndrome in sickle cell disease with the anti-IL6R humanised monoclonal antibody tocilizumab. Hyperhaemolysis syndrome (HHS) is a severe post-transfusion complication that can develop rapidly and cause life-threatening anaemia and death unless recognised and treated promptly.1,2 It is mostly, but not exclusively, seen in sickle cell patients, often after multiple previous transfusions. [Extracted from the article]